Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR2 | Q969V1 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30573675 | 1.00 | MCHR2 (0.46) | MCHR2SIGMAR1HTR2AHTR2CDRD2 | |
| Hydrochloric Acid SCHEMBL6976186 | 0.98 | MCHR2 (0.45) | MCHR2SIGMAR1HTR2AHTR2CDRD2 | |
| Hydrochloric Acid SCHEMBL6973147 | 0.98 | MCHR2 (0.45) | MCHR2SIGMAR1HTR2AHTR2CDRD2 | |
| SCHEMBL27213034 | 0.80 | MCHR2 (0.40) | MCHR2SIGMAR1HTR2AHTR2CKDM1A | |
| SCHEMBL29993139 | 0.80 | KDM1A (0.53) | SIGMAR1HTR2AHTR2CDRD2SLC6A2 | |
| SCHEMBL21920651 | 0.80 | KDM1A (0.53) | SIGMAR1HTR2AHTR2CDRD2SLC6A2 | |
| SCHEMBL21383813 | 0.80 | KDM1A (0.53) | SIGMAR1HTR2AHTR2CDRD2SLC6A2 | |
| SCHEMBL10092817 | 0.79 | MCHR2 (0.50) | MCHR2SIGMAR1HTR2AHTR2CKDM1A | |
| SCHEMBL31415670 | 0.78 | KDM1A (0.44) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL30232495 | 0.75 | SIGMAR1 (0.44) | SIGMAR1HTR2AHTR2CDRD2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747251-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025019479-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| EP-3601239-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172984-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2018-09-27 | — | — | WO | disclosed |
| US-7354925-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7279486-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | PFIZER, INC. | 2007-08-23 | — | — | US | disclosed |
| EP-1732893-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | Pfizer Japan, Inc. (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
| WO-2005092858-A2 | ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST | PFIZER JAPAN INC. (JP) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | OPRL1, OGFRL1, ORMDL3 | MCHR2 1239/4885SIGMAR1 10/4885HTR2A 2173/4885 |
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | OPRL1, OPRD1, OPRK1 | MCHR2 1241/4885SIGMAR1 26/4885HTR2A 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.